bioRxiv Science⌕ Search

Biology subjects

Hungnes, O.

Publications and source records attributed to Hungnes, O..

3 recordsLinked to original sources

Highly Pathogenic Avian Influenza A(H5N1) Caused Mass Death among Black-legged Kittiwakes (Rissa tridactyla) in Norway, 2023

In 2023, highly pathogenic avian influenza (HPAI) heavily affected gulls in Europe. In July, a mass mortality event was reported in the Black-legged Kittiwake (Rissa tridactyla) breeding colony at Ekkeroy in Northern Norway. The cause was confirmed to be infection with the HPAI H5N1 clade 2.3.4.4b virus, genotype EA-2022-BB. We describe the outbreak in Kittiwakes, including pathological and virological investigations, and discuss the management and zoonotic potential. With more than 15,000 dead birds reported, we estimate that the outbreak caused a reduction in the Kittiwake population at Ekkeroy of at least 50%. Diseased birds exhibited neurological signs. Necropsy of ten birds revealed a peracute fatal systemic disease, with severe lesions in the brain and pancreas co-localizing with the presence of viral RNA and antigen. Vascular expression of 2,3-linked sialic acids and viral RNA/antigen may reflect hematogenous virus spread. Further studies should investigate the long-term impact of HPAI on Kittiwake populations.

microbiology↗

Low levels of neutralizing antibodies against SARS-CoV-2 KP.3.1.1 and XEC in serum from seniors in May 2024

New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that are either widely distributed or on the rise globally, in sera from a cohort of seniors aged 68 - 82 years from April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, supporting the recommendation of an updated covid-19 vaccine booster in this age group.

immunology↗

Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022

New sub-lineages of the SARS-CoV-2 omicron variants with enhanced ability to evade existing antibody responses continue to evolve. A better understanding how susceptible emerging virus variants are to immunity induced by vaccination or infection could help predict which strains will become dominant going forward. Here we evaluate neutralizing antibodies against several clinical isolates of omicron variants including BQ.1.1 and XBB in sera from 3x mRNA vaccinated individuals and individuals with breakthrough infections with early (BA.1 or 2) or late (BA.5) omicron variants. In addition, we evaluate neutralizing antibodies in serum samples harvested from 32 individuals from the middle of October 2022, to provide a more recent estimate of immunity. As expected, serum samples harvested after breakthrough infections were more efficient at neutralizing all the omicron variants, compared to sera from non-infected individuals. While neutralization remained high against variants such as BA.2.75.2, BR.1 and BF.7, there was a marked reduction in neutralizing titers against BQ.1.1 and XBB. Similarly, most serum samples harvested in October 2022 had very low neutralizing antibodies against BQ.1.1 and XBB, suggesting that these variants and their descendants will dominate infection waves in Norway this winter season.

immunology↗